Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Castle Biosciences to Present at Upcoming Investor Conferences


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences:

Live audio webcasts of the company's presentations will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/events-presentations. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq; www.MyUvealMelanoma.com), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.


These press releases may also interest you

at 20:12
The food recall warning issued on August 1, 2020 has been updated to include additional distribution information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Industry is...

at 19:16
Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative...

at 19:15
The "Syringe and Needle Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global syringe and needle market is expected to grow at a CAGR of over 10% during the period 2019-2025 The global...

at 19:00
The "US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering. The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period...

at 18:15
The "Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020" report has been added to ResearchAndMarkets.com's offering. The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to...

at 18:10
Service Corporation International (the "Company") announces that the previously announced cash tender offer for any and all of its 5.375% Senior Notes due 2024 (CUSIP No. 817565 CB8/ ISIN No. US817565CB82) (the "Notes"), which expired today at 5:00...



News published on 20 november 2019 at 07:05 and distributed by: